Hemab Therapeutics: The Market Is Pricing One Rung Of A Four-Rung Ladder (NASDAQ:COAG)
· seekingalpha.com
Hemab Therapeutics (COAG) investment overview: sutacimig cut bleeds ~84% in GT; Phase 3 in 2H 2026; VWD/HMB upside & key risks.
I last covered Hemab roughly two and a half months ago, in mid-July. Since then, the company has reported second-quarter results showing $457.5 million in cash ...